Inovio » About Us » Leadership » Biography

"Immunization ranks among the most important health advances of the 20th century. With the exception of safe drinking water, vaccinology has more effectively reduced mortality than any other modality."

"Extraordinary advances in biotechnology make DNA vaccines the most promising area of vaccinology."

Advances in DNA vaccines
Nurse Practitioner
James Mark Simmerman
Jan 2002

"I have stated in public seminars that, in my opinion, electroporation is the gold standard for DNA vaccine delivery, giving us the best result in terms of immunogenicity of DNA vaccines."

George N. Pavlakis, MD, PhD
Chief
Human Retrovirus Section, Vaccine Branch
National Cancer Institute

home » about us » leadership » avtar dhillon

Biography

Avtar Dhillon, M.D.
President and CEO, Inovio Biomedical

AVTAR DHILLON, M.D., joined Inovio as President, Chief Executive Officer and Director in October 2001. Prior to joining Inovio, Dr. Dhillon was engaged by MDS Capital Corp. (now Lumira Capital Corp.) as a consultant in July 1998 and subsequently became an investment manager in August 1999 and Vice President in 2000. MDS Capital Corp. (now Lumira Capital Corp.) is one of North America's leading healthcare venture capital organizations. In July 1989, Dr. Dhillon started a medical clinic and subsequently practiced family medicine for over 12 years. From March 1997 to July 1998, Dr. Dhillon acted as consultant to Cardiome Pharma Corp., a biotechnology company listed on the Toronto Stock Exchange and NASDAQ. Dr. Dhillon has a Bachelor of Science, Honors, in human physiology and M.D. from the University of British Columbia.